Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Ichiro MisumiDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3892-7605
You LiDepartment of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-5458-6009
Takayoshi ShirasakiLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Lixin YangDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Maryna KapustinaDepartment of Cell Biology & Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Stanley M LemonLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1450-806X
Jason K WhitmireDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-2578-6073
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Membrane Hijacking: Biogenesis and Fate of Quasi-Enveloped HepatovirusR01AI103083 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEMON, STANLEY M. · 2012 to 2021
$4.0M
Regulation of CD8+ T cell responses to chronic virus infectionR01AI143894 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WHITMIRE, JASON KYLE · 2019 to 2023
$2.5M
Obesity associated viral pathogenesisR01AI138337 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WHITMIRE, JASON KYLE · 2018 to 2022
$1.9M
Murine Model of Human Hepatitis AR01AI131685 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEMON, STANLEY M., WHITMIRE, JASON KYLE · 2017 to 2021
$1.9M
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) InfectionR41AI177204 · NIAID · HARLINGENE LIFE SCIENCES LLC · PI DU, YANMING · 2023 to 2024
$600k
Antiviral inhibition of ZCCHC14-TENT4 complex in hepatitis A virus infectionR21AI163606 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, YOU, MISUMI, ICHIRO · 2021 to 2022
A limited number of studies on human subjects with type-A hepatitis have found a positive correlation between activated natural killer (NK) cell frequencies in blood and the severity of liver injury. However, without knowledge of differences in viral burdens, it remains unclear whether NK cells are elevated due to hepatitis A virus (HAV) replication and ongoing associated injury, or if NK cell responses directly cause pathogenesis. To gain insight into how NK cells respond during the early stages of hepatitis A virus infection, we generated mice that are permissive for HAV infection in the liver but are otherwise immunocompetent. HAV readily infected the liver of these hepatocyte-specific type-I interferon receptor knockout mice (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Natural killer cells and IFN-γ protect against liver injury during HAV infection in mice. · full record | OpenQuestion